Telix Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Telix Pharmaceuticals has a total shareholder equity of A$404.0M and total debt of A$11.9M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are A$746.0M and A$342.0M respectively. Telix Pharmaceuticals's EBIT is A$67.4M making its interest coverage ratio -64.7. It has cash and short-term investments of A$118.8M.
Belangrijke informatie
2.9%
Verhouding schuld/eigen vermogen
AU$11.85m
Schuld
| Rente dekkingsratio | -64.7x |
| Contant | AU$118.84m |
| Aandelen | AU$403.97m |
| Totaal verplichtingen | AU$341.98m |
| Totaal activa | AU$745.96m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: TLX's short term assets (A$255.3M) do not cover its short term liabilities (A$258.4M).
Langlopende schulden: TLX's short term assets (A$255.3M) exceed its long term liabilities (A$83.6M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: TLX has more cash than its total debt.
Schuld verminderen: TLX's debt to equity ratio has reduced from 3.3% to 2.9% over the past 5 years.
Schuldendekking: TLX's debt is well covered by operating cash flow (419.4%).
Rentedekking: TLX earns more interest than it pays, so coverage of interest payments is not a concern.